ONCOLOGY Vol 26 No 2 | Oncology

The Maze of PARP Inhibitors in Ovarian Cancer

February 10, 2012

The development of poly(ADP-ribose) polymerase (PARP) inhibitors as a new class of anticancer agents has created a tremendous amount of hope in the ovarian cancer community, especially in the high-risk, difficult-to-screen, hereditary ovarian cancer population.

AL Amyloidosis: New Drugs and Tests, but Old Challenges

February 09, 2012

Immunoglobulin light chain (AL) amyloidosis develops in 2% of individuals with monoclonal plasma cell dyscrasias. In this issue of ONCOLOGY, Drs. Gertz and Dispenzieri discuss AL amyloidosis, highlighting progress in the field along with outstanding challenges.

Formidable Challenges Ahead for Lung Cancer Screening

February 09, 2012

Tanner et al provide a concise review of lung cancer screening, including discussion of past failed attempts, the success of the National Lung Screening Trial (NLST), and promising new avenues for improving on the NLST results.

Vismodegib Granted FDA Approval for Treatment of Basal Cell Carcinoma

February 01, 2012

The US Food and Drug Administration (FDA) announced the approval of vismodegib (Erivedge), for the treatment of advanced basal cell carcinoma, the most common type of skin cancer, for patients who are not eligible for surgery or radiation, and for metastatic disease.

New Testing for Lung Cancer Screening

February 15, 2012

In this review, the authors discuss past attempts at lung cancer screening, the results of the National Lung Cancer Screening Trial, and innovative tests for lung cancer screening currently being evaluated.

Immunoglobulin Light-Chain Amyloidosis: Growing Recognition, New Approaches to Therapy, Active Clinical Trials

February 15, 2012

When light-chain amyloidosis is diagnosed prior to the development of advanced cardiomyopathy, systemic therapy is capable of producing hematologic responses that will translate into organ responses and prolonged survival. Advances in the management of multiple myeloma are currently being translated into a variety of clinical trials designed to improve the quality of life and survival of patients with light-chain amyloidosis.

PARP Inhibition in Epithelial Ovarian Cancer: High Hopes Undergo a Reality Check

February 15, 2012

This article reviews the trials that have been conducted with PARP inhibitors in epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer, and places the impact of those results in the larger context of PARP inhibitor development.